AlloVir Inc. (ALVR) News
Filter ALVR News Items
ALVR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALVR News Highlights
- ALVR's 30 day story count now stands at 4.
- Over the past 21 days, the trend for ALVR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- TOP, ARM and DEC are the most mentioned tickers in articles about ALVR.
Latest ALVR News From Around the Web
Below are the latest news stories about ALLOVIR INC that investors may wish to consider to help them evaluate ALVR as an investment opportunity.
Karuna downgraded, Arm target raised: Wall Street's top analyst callsKaruna downgraded, Arm target raised: Wall Street's top analyst calls |
Nike downgraded, Waste Management upgraded: Wall Street's top analyst callsNike downgraded, Waste Management upgraded: Wall Street's top analyst calls |
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell TherapyCompany to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell i |
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger PotentialThere are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change. |
AlloVir to Present at the Piper Sandler 35th Annual Healthcare ConferenceWALTHAM, Mass., November 16, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET. |
AlloVir Inc (ALVR) Reports Q3 2023 Financial ResultsCompany's Cash Position Strengthens, Paving the Way for Pivotal Trial Data Readouts |
AlloVir Reports Third Quarter 2023 Financial ResultsWALTHAM, Mass., November 02, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30, 2023. AlloVir continues to progress its highly innovative lead therapeutic candidate, posoleucel, by enrolling globally in three Phase 3 trials for first-to-market indications. AlloVir is in a position of strength with significant financial resources to support operations through topline data re |
Why AlloVir Stock Dropped TodayAlloVir briefly plunged amid concerns over selling pressure related to a recent lock-up agreement expiration. |
We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
These 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say AnalystsLet’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi |